RxDoctor Payments Data

Abbas Khalil, MD

Hematology-Oncology · Lima, OHNPI 1093716698

Payments from drug & device makers

$2,475in general payments, 2019–2025

Across 130 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$332
  • Novartis$274
  • Johnson & Johnson$270
  • AVEO Pharmaceuticals, Inc.$167
  • Amgen$160
  • Pfizer$154
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,13186%
  • Education$34414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few hematology-oncology providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,965,805
Medicare patients
299
Services billed
65,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib35$552,158
RevlimidLenalidomide23$392,340
JakafiRuxolitinib Phosphate16$271,413
BrukinsaZanubrutinib15$228,944
SprycelDasatinib12$214,163
Lenalidomide15$210,445
Imatinib Mesylate26$74,646
EliquisApixaban31$28,466
XareltoRivaroxaban23$17,331
Hydroxyurea46$1,351
Ondansetron Hcl26$706
Letrozole13$233
Anastrozole20$176
Levothyroxine Sodium13$96
Warfarin Sodium15$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$85$552,15835 claims
Bristol Myers SquibbRevlimid$153$392,34023 claims
E.r. Squibb & Sons, L.L.C.Sprycel$332$214,16312 claims
PfizerEliquis$154$28,46631 claims
Johnson & JohnsonXarelto$270$17,33123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other hematology-oncology in Lima

Where these figures come from

Is this you, or does something look wrong? →